Security Snapshot

Enliven Therapeutics, Inc. - Common Stock, par value $0.001 per share (ELVN) Institutional Ownership

CUSIP: 29337E102

13F Institutional Holders and Ownership History from Q1 2023 to Q1 2026

Latest Period

Q4 2025

Institutions Reporting

125

Shares (Excl. Options)

62,391,024

Price

$15.40

Save this security page for your next review

Keep this CUSIP in your watchlists so you can revisit quarter changes from one place.

Create free account to save this page Review latest holder period
Type / Class
Equity / Common Stock, par value $0.001 per share
Symbol
ELVN on Nasdaq
Shares outstanding
58,923,077
Price per share
$39.20
All holders as of 31 Dec 2025
Q4 2025
Total 13F shares
62,391,024
Total reported value
$960,824,930
% of total 13F portfolios
0%
Share change
+2,259,081
Value change
+$20,216,707
Number of holders
125
Price from insider filings
$39.20
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors

Sponsored

Quick Takeaways

  • ELVN - Enliven Therapeutics, Inc. - Common Stock, par value $0.001 per share is tracked under CUSIP 29337E102.
  • 125 institutions reported positions in Q4 2025.
  • 8 significant owners is listed from Schedule 13D/13G reporting.

What Changed

  • Holder count moved from 125 to 7 between Q4 2025 and Q1 2026.
  • Reported value moved from $960,824,930 to $1,858,506.

Why This Matters

  • You can quickly see who holds this security, then open quarter and manager detail pages for full evidence.
  • 13F and Schedule 13D/13G sections are kept together so you can cross-check institutional and beneficial ownership context.

Source Evidence

Source: SEC Form 13F

Latest holder context comes from 125 institutions filings for Q4 2025.

Open SEC Evidence

Investment Quick Answers

What is CUSIP 29337E102?
CUSIP 29337E102 identifies ELVN - Enliven Therapeutics, Inc. - Common Stock, par value $0.001 per share in SEC 13F datasets.

Where can I see the latest institutional holders?
Review the Q4 2025 holders report and the ownership history table below.

Significant Owners of Enliven Therapeutics, Inc. - Common Stock, par value $0.001 per share (ELVN) based on Schedule 13D/G filings

Filer Ownership Change % Holdings Value Net Change Nb Shares Change % Reporting Name Report Period
ORBIMED ADVISORS LLC 13% $140,468,212 7,918,163 ORBIMED ADVISORS LLC 16 Jun 2025
FMR LLC 13% $161,103,383 7,870,219 FMR LLC 30 Sep 2025
Commodore Capital LP 9.9% $135,215,385 6,022,957 Commodore Capital LP 30 Jun 2025
Vestal Point Capital, LP 6.5% $98,622,500 3,830,000 Vestal Point Capital, LP 31 Dec 2025
Fairmount Funds Management LLC 6.3% -4.3% $83,321,918 +$11,419,103 3,711,444 +16% Fairmount Funds Management LLC 30 Jun 2025
Venrock Healthcare Capital Partners III, L.P. 5.4% $66,042,996 3,226,331 Venrock Healthcare Capital Partners III, L.P. 30 Sep 2025
BlackRock, Inc. 5.1% $59,005,266 2,941,395 BlackRock, Inc. 30 Jun 2025
Polar Capital Holdings Plc 5.2% +5.6% $56,952,978 +$3,304,932 2,536,881 +6.2% Polar Capital Holdings Plc 30 Jun 2025

As of 31 Dec 2025, 125 institutional investors reported holding 62,391,024 shares of Enliven Therapeutics, Inc. - Common Stock, par value $0.001 per share (ELVN). This represents 106% of the company’s total 58,923,077 outstanding shares.

Top 25 Institutional Shareholders

The largest institutional shareholders of Enliven Therapeutics, Inc. - Common Stock, par value $0.001 per share (ELVN) together control 96% of the company’s outstanding shares — a level of ownership often associated with strong institutional conviction and long‑term capital commitment.

Institution Ownership % Shares Held Share Change % Portfolio % Holdings Value
ORBIMED ADVISORS LLC 14% 7,959,538 0% 2.6% $122,576,885
FMR LLC 12% 7,107,635 -0.3% 0.01% $109,457,572
Commodore Capital LP 8% 4,692,809 0% 4.8% $72,269,259
Vestal Point Capital, LP 6.5% 3,830,000 +230% 2.2% $58,982,000
Fairmount Funds Management LLC 6.3% 3,711,444 0% 4.4% $57,156,238
BlackRock, Inc. 6.1% 3,613,326 +2.7% 0% $55,645,219
Polar Capital Holdings Plc 6% 3,513,680 +14% 0.25% $54,110,672
VR ADVISER, LLC 5.5% 3,226,331 0% 2.5% $49,685,497
VANGUARD GROUP INC 4.8% 2,801,665 +9.7% 0% $43,145,640
JANUS HENDERSON GROUP PLC 2.8% 1,671,724 -6.8% 0.01% $25,744,550
Point72 Asset Management, L.P. 2.6% 1,504,601 +45% 0.04% $23,170,855
NOVO HOLDINGS A/S 2.5% 1,480,000 +3.8% 1.8% $22,792,000
CITADEL ADVISORS LLC 2.4% 1,424,344 +23% 0.01% $21,934,897
Capital Research Global Investors 2.2% 1,304,346 -0.85% 0% $20,086,928
Pictet Asset Management Holding SA 2.2% 1,303,235 -6.8% 0.02% $20,069,819
STATE STREET CORP 1.8% 1,052,862 +9.1% 0% $16,214,075
GEODE CAPITAL MANAGEMENT, LLC 1.8% 1,048,722 -3.3% 0% $16,153,779
Soleus Capital Management, L.P. 1.7% 1,025,000 0.67% $15,785,000
Blackstone Inc. 1.6% 954,946 -28% 0.06% $14,706,168
Rock Springs Capital Management LP 1.4% 798,405 +16% 0.63% $12,295,437
5AM Venture Management, LLC 1.3% 772,477 0% 3.7% $11,896,146
Candriam S.C.A. 0.77% 453,019 -26% 0.03% $6,976,790
Spruce Street Capital LP 0.76% 446,084 0% 2.3% $6,869,694
MORGAN STANLEY 0.7% 411,823 +59% 0% $6,342,080
DIMENSIONAL FUND ADVISORS LP 0.68% 398,893 +149% 0% $6,143,418

Institutional Holders of Enliven Therapeutics, Inc. - Common Stock, par value $0.001 per share (ELVN) across Reporting Periods

Period Reported Shares, Excl. Options Value, Excl. Options Value Change Price (Median) Investors
2026 Q1 47,440 $1,858,506 +$1,766,141 $39.20 7
2025 Q4 62,391,024 $960,824,930 +$20,216,707 $15.40 125
2025 Q3 59,389,507 $1,215,687,864 -$296,366 $20.47 132
2025 Q2 59,434,902 $1,192,251,085 +$192,194,924 $20.06 123
2025 Q1 49,886,849 $983,923,667 +$4,352,699 $19.68 118
2024 Q4 49,624,914 $1,116,597,658 +$24,828,957 $22.50 111
2024 Q3 47,688,348 $1,218,010,157 -$20,810,259 $25.54 100
2024 Q2 48,318,843 $1,129,194,355 +$91,652,714 $23.37 91
2024 Q1 44,456,336 $780,753,492 +$95,045,035 $17.59 72
2023 Q4 39,000,634 $539,791,932 -$652,659 $13.84 61
2023 Q3 39,076,502 $533,779,750 -$2,178,662 $13.66 60
2023 Q2 39,092,843 $797,915,923 +$112,876,379 $20.41 61
2023 Q1 33,557,749 $734,910,999 +$734,911,000 $21.90 44

Sponsored